BSG issues guideline on acute lower gastrointestinal bleeding

  • Oakland K & al.
  • Gut
  • 12 Feb 2019

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The British Society of Gastroenterology (BSG) has issued the first UK national guideline to concentrate on acute lower gastrointestinal bleeding (LGIB).

Key recommendations include:

  • Stratify LGIB as stable or unstable (shock index >1) and stable bleeds as major or minor.
  • Patients with minor self-terminating bleed and no other indications can be discharged for urgent outpatient investigation.
  • Admit patients with major bleed for colonoscopy.
  • CT angiography (CTA) before endoscopy or radiology in patients with haemodynamic instability after initial resuscitation and/or suspected active bleeding.
  • Immediate upper endoscopy for haemodynamically unstable LGIB if no source is identified by initial CTA.
  • Catheter angiography as soon as possible after positive CTA.
  • In general, emergency laparotomy should not be performed unless every effort has been made to localise bleeding with radiology and/or endoscopy.
  • In stable patients (without a history of cardiovascular disease) requiring transfusion, a threshold of haemoglobin trigger of 70 g/L and Hb concentration target of 70-90 g/L after transfusion should be used.
  • Interrupt warfarin at presentation. In unstable gastrointestinal haemorrhage, reverse anticoagulation with prothrombin complex concentrate and vitamin K.
  • In patients with high thrombotic risk, consider low molecular weight heparin 48 hours after haemorrhage.
  • Permanently discontinue aspirin for primary CVD prophylaxis.
  • Do not routinely stop aspirin for secondary prevention.
  • Do not routinely stop dual P2Y12 receptor antagonist and aspirin therapy in patients with coronary stents.
  • In unstable haemorrhage, continue aspirin if P2Y12 antagonist is interrupted.
  • Interrupting direct oral anticoagulant therapy at presentation. Considering treatment with idarucizumab or andexanet for life-threatening haemorrhage on direct oral anticoagulants.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.